READ-POAF Pilot Studies Postoperative Atrial Fibrillation After Cardiac Surgery
| Tracking Information | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First Received Date ICMJE | February 8, 2012 | ||||||||||||
| Last Updated Date | August 31, 2012 | ||||||||||||
| Start Date ICMJE | March 2012 | ||||||||||||
| Estimated Primary Completion Date | February 2013 (final data collection date for primary outcome measure) | ||||||||||||
| Current Primary Outcome Measures ICMJE |
atrial fibrillation (AF) [ Time Frame: 3 months ] [ Designated as safety issue: No ] frequency, frequency distribution, and burden of AF |
||||||||||||
| Original Primary Outcome Measures ICMJE |
atrial fibrillation (AF) [ Time Frame: 3 months ] [ Designated as safety issue: No ] frequency, frequencydistribution, and burden of AF |
||||||||||||
| Change History | Complete list of historical versions of study NCT01530750 on ClinicalTrials.gov Archive Site | ||||||||||||
| Current Secondary Outcome Measures ICMJE |
atrial fibrillation (AF) [ Time Frame: 12 months ] [ Designated as safety issue: No ] frequency, frequency distribution, burden of AF, AF substrate |
||||||||||||
| Original Secondary Outcome Measures ICMJE |
atrial fibrillation (AF) [ Time Frame: 12 months ] [ Designated as safety issue: No ] frequency, frequencydistribution, and burden of AF |
||||||||||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||||||||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||||||||||
| Descriptive Information | |||||||||||||
| Brief Title ICMJE | READ-POAF Pilot Studies Postoperative Atrial Fibrillation After Cardiac Surgery | ||||||||||||
| Official Title ICMJE | READ-POAF Pilot Study. The Use of the Reveal XT as Device for Postoperative Atrial Fibrillation Detection After Cardiac Surgery | ||||||||||||
| Brief Summary | Postoperative atrial fibrillation after coronary artery bypass grafting will be monitored up to 1 year after the procedure by implanting a Reveal XT internal loop recorder two weeks before the surgery. Frequency, burden, and possible risk factors will be described. During the operation direct contact epicardial mapping will be performed and tissue samples will be collected to identify an electrophysiological and a structural substrate for development of AF. |
||||||||||||
| Detailed Description | Background of the study: Postoperative atrial fibrillation (POAF) after cardiac surgery is a common (1 in 4) complication and associated with morbidity and mortality. Not all episodes of AF are noticed and detected, especially after discharge. several studies have shown high mortality in POAF patients, suggesting a progression in AF frequency. Objective of the study: To investigate the real incidence and burden of POAF. Afterwards a risk stratification of POAF is made. To identify a structural and electrophysiological substrate for the development of POAF and new onset AF during follow up. Study design: 140 patients will receive a Reveal device. After 3 and 12 months data will be subtracted from the device. 100 of these patient will undergo additional mapping and tissue biopsies during operation. Study population: All patients undergoing cardiac surgery without a history of AF and without a pacemaker will be invited to participate in the study. Primary study parameters/outcome of the study: Incidence of POAF until 3 months after CABG. Secondary study parameters/outcome of the study: Incidence of POAF until 12 months after CABG. Determine risk factors for early and late POAF. Detect pre-operative (unnoticed) episodes of AF. Determine a substrate for development of AF. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: There is a small risk of minor complications (hemorrhage and infection of the pocket).The device can be explanted easily if necessary. Ther is a burden of the im- and explantation of the device (local anesthesia, approx. 20 minutes). Patient will have to visit the out-hospital clinic twice. The operation will be prolonged by 30 minutes due to mapping. |
||||||||||||
| Study Type ICMJE | Observational | ||||||||||||
| Study Design ICMJE | Observational Model: Cohort Time Perspective: Prospective |
||||||||||||
| Target Follow-Up Duration | Not Provided | ||||||||||||
| Biospecimen | Not Provided | ||||||||||||
| Sampling Method | Non-Probability Sample | ||||||||||||
| Study Population | those patients undergoing cardiac surgery. |
||||||||||||
| Condition ICMJE | Atrial Fibrillation | ||||||||||||
| Intervention ICMJE | Not Provided | ||||||||||||
| Study Group/Cohort (s) | Post cardiac surgery | ||||||||||||
| Publications * | Not Provided | ||||||||||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||
| Recruitment Information | |||||||||||||
| Recruitment Status ICMJE | Recruiting | ||||||||||||
| Estimated Enrollment ICMJE | 40 | ||||||||||||
| Estimated Completion Date | February 2014 | ||||||||||||
| Estimated Primary Completion Date | February 2013 (final data collection date for primary outcome measure) | ||||||||||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||||||
| Gender | Both | ||||||||||||
| Ages | 60 Years to 90 Years | ||||||||||||
| Accepts Healthy Volunteers | No | ||||||||||||
| Contacts ICMJE |
|
||||||||||||
| Location Countries ICMJE | Netherlands | ||||||||||||
| Administrative Information | |||||||||||||
| NCT Number ICMJE | NCT01530750 | ||||||||||||
| Other Study ID Numbers ICMJE | NL37204.060.11 | ||||||||||||
| Has Data Monitoring Committee | No | ||||||||||||
| Responsible Party | Catharina Ziekenhuis Eindhoven | ||||||||||||
| Study Sponsor ICMJE | Catharina Ziekenhuis Eindhoven | ||||||||||||
| Collaborators ICMJE | Maastricht University Medical Center | ||||||||||||
| Investigators ICMJE |
|
||||||||||||
| Information Provided By | Catharina Ziekenhuis Eindhoven | ||||||||||||
| Verification Date | August 2012 | ||||||||||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||||||||||